Saad Munib Ahmed Khan, MD
Medical Oncology · Stanford
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 17
- 3 carriers
- Office
- 1
- Since medical school
- 23 years
- Graduated 2003
Offices
1 location · Stanford Health Care · 3,152 clinicians in this group
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
17 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Khan’s office at (650) 723-4000 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
17 of 17 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| SCAN Balance (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Classic (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN MyChoice (HMO) | SCAN Health Plan | Listed | Oct 3, 2026 |
| SCAN Strive (HMO C-SNP) | SCAN Health Plan | Listed | Oct 3, 2026 |
| DualConnect (HMO D-SNP) | Santa Clara Family Health Plan | Listed | Sep 1, 2026 |
California Medical Board record
Licence C164010 · Current
Licensed to practise in California · since 2019 · expires 2027-08-31 · University of the Punjab, Punjab Medical College.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
State licence records
1 licence
- Texas P3742Physician License · since 2012 · expires 2028-08-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- American Board of Internal Medicine - Hematology
- American Board of Internal Medicine - Medical Oncology
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$103,641
Medicare paid this office $103,641 for 216 people. Most of that is long return visits and Botox.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Long return visit (40+ min) | 132 | $59,532 | $126 |
| Long return visit (40+ min) | 42 | $11,369 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $9,777 | $105 |
| New patient visit (60+ min) | 44 | $7,007 | $159 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,321 | $154 |
See all 9 services
| Long return visit (40+ min) | 132 | $59,532 | $126 |
| Long return visit (40+ min) | 42 | $11,369 | $172 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 28 | $9,777 | $105 |
| New patient visit (60+ min) | 44 | $7,007 | $159 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 38 | $6,321 | $154 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 98 | $4,105 | $15 |
| Return visit (30+ min) | 16 | $1,986 | $124 |
| Return visit (30+ min) | 16 | $1,494 | $83 |
| Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | 29 | $704 | $15 |
Who their Medicare patients are
216 Original Medicare patients in 2024. Average age 73 · Under 65 10% · 85 and older 9% · Women 43% · Also on Medicaid 25% · Health risk score 2.55. Above the middle of the specialty; the typical medical oncology clinician is at 2.11.
Conditions among them: High blood pressure 73% · Coronary heart disease 29% · Diabetes 27% · Cancer 24% · Chronic kidney disease 22% · Depression 20% · Heart failure 19% · Atrial fibrillation 19% · COPD 11% · Dementia 11% · Stroke 8%.
The office billed $283,038, Medicare allowed $132,887 and paid $103,641; for 1,086 services of 10 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 216 | 1,086 | 73 | 2.55 | $283,038 | $103,641 |
| 2023 | 218 | 853 | 74 | 2.42 | $224,728 | $103,693 |
| 2022 | 152 | 521 | 74 | 2.14 | $157,340 | $58,323 |
| 2021 | 181 | 590 | 73 | 2.15 | $154,704 | $62,314 |
| 2020 | 112 | 292 | 73 | 3.07 | $94,580 | $28,672 |
| 2019 | 177 | 739 | 73 | 3.46 | $243,021 | $74,806 |
| 2018 | 212 | 882 | 73 | 2.98 | $288,725 | $93,229 |
| 2017 | 181 | 728 | 72 | 3.14 | $213,526 | $70,147 |
| 2016 | 156 | 557 | 71 | 2.74 | $164,390 | $51,492 |
| 2015 | 119 | 416 | 70 | 3.13 | $132,186 | $31,938 |
| 2014 | 132 | 434 | 70 | 2.37 | $138,614 | $35,460 |
| 2013 | 110 | 345 | 68 | 2.60 | $114,357 | $28,272 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 6 services
| Long return visit (40+ min) | 139 | $64,479 | $131 |
| Return visit (30+ min) | 96 | $12,910 | $81 |
| New patient visit (60+ min) | 66 | $11,064 | $168 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $10,751 | $110 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 14 | $2,559 | $160 |
| Hospital discharge day management, 30 minutes or less | 11 | $911 | $76 |
2022: 4 services
| Long return visit (40+ min) | 63 | $19,245 | $125 |
| Return visit (30+ min) | 71 | $17,373 | $86 |
| New patient visit (60+ min) | 55 | $9,156 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 33 | $6,061 | $178 |
2021: 4 services
| Return visit (30+ min) | 122 | $32,876 | $88 |
| Long return visit (40+ min) | 68 | $14,954 | $131 |
| New patient visit (60+ min) | 53 | $8,819 | $166 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 12 | $2,426 | $187 |
2020: 6 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 20 | $9,251 | $157 |
| Return visit (30+ min) | 31 | $5,999 | $73 |
| New patient visit (60+ min) | 18 | $2,838 | $158 |
| Long return visit (40+ min) | 30 | $2,307 | $61 |
| Long return visit (40+ min) | 11 | $1,781 | $105 |
| Return visit (30+ min) | 24 | $1,645 | $53 |
2019: 6 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 51 | $36,534 | $157 |
| Long return visit (40+ min) | 78 | $15,573 | $86 |
| Return visit (30+ min) | 95 | $11,932 | $57 |
| New patient visit (60+ min) | 36 | $4,584 | $127 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $2,817 | $83 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 23 | $1,449 | $58 |
2018: 7 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 58 | $45,158 | $157 |
| Return visit (30+ min) | 103 | $15,076 | $61 |
| Long return visit (40+ min) | 63 | $12,301 | $86 |
| New patient visit (60+ min) | 54 | $7,268 | $135 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 31 | $4,961 | $160 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $4,523 | $82 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $1,920 | $58 |
2017: 8 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 38 | $23,050 | $157 |
| Long return visit (40+ min) | 66 | $12,916 | $86 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 47 | $10,336 | $81 |
| Return visit (30+ min) | 67 | $8,298 | $59 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 35 | $5,159 | $147 |
| New patient visit (60+ min) | 33 | $4,301 | $130 |
| Return visit (30+ min) | 11 | $1,750 | $58 |
| Hospital discharge day management, 30 minutes or less | 12 | $637 | $53 |
2016: 7 services
| Oncology care model (ocm) monthly enhanced oncology services (meos) payment for ocm enhanced services. g9678 payments may only be made to ocm practitioners for ocm beneficiaries for the furnishment of enhanced services as defined in the ocm participation a | 20 | $13,014 | $157 |
| Long return visit (40+ min) | 55 | $8,853 | $84 |
| Return visit (30+ min) | 55 | $8,796 | $59 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 34 | $7,596 | $83 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 30 | $5,022 | $157 |
| New patient visit (60+ min) | 28 | $3,751 | $134 |
| Hospital discharge day management, more than 30 minutes | 14 | $1,193 | $85 |
2015: 6 services
| Long return visit (40+ min) | 53 | $9,821 | $85 |
| Return visit (30+ min) | 58 | $7,658 | $55 |
| New patient visit (60+ min) | 32 | $4,293 | $134 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 20 | $3,041 | $145 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 15 | $2,761 | $55 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 16 | $2,735 | $80 |
2014: 8 services
| Long return visit (40+ min) | 43 | $9,216 | $82 |
| Return visit (30+ min) | 52 | $6,900 | $61 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 32 | $5,140 | $161 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,945 | $82 |
| New patient visit (60+ min) | 25 | $3,142 | $126 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 20 | $2,168 | $57 |
| Hospital discharge day management, more than 30 minutes | 17 | $1,526 | $85 |
| Initial hospital care with straightforward or low-level medical decision making at least 55 minutes | 12 | $1,416 | $109 |
2013: 7 services
| Long return visit (40+ min) | 33 | $8,156 | $81 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 27 | $4,204 | $156 |
| Return visit (30+ min) | 35 | $3,949 | $59 |
| New patient visit (60+ min) | 29 | $3,576 | $123 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 19 | $3,038 | $78 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 19 | $2,325 | $55 |
| Hospital discharge day management, 30 minutes or less | 14 | $786 | $56 |
Medicaid work
$7,339 in 2024
Medicaid paid $7,339 for 147 billed services this clinician did in 2024, up to 15 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Long return visit (40+ min) | 147 | $7,339 |
| 2024 | 147 | 1 | 15 | $7,339 |
| 2023 | 183 | 2 | 16 | $7,415 |
| 2021 | 55 | 1 | 17 | $1,637 |
See the largest Medicaid services in earlier years
2023
| Long return visit (40+ min) | 153 | $6,873 |
| Return visit (30+ min) | 30 | $542 |
2021
| Return visit (30+ min) | 55 | $1,637 |
Drugs they prescribed that Part D paid
$1,509,955
Pharmacies billed $1,509,955 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 7% of their Part D prescriptions (19 of 272) in 2024. Above the middle of the specialty; the typical medical oncology clinician is at 6%.
170 generic and fewer than 11 brand-name prescriptions · $1,509,955 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lenvima | 32 | $725,335 | $22,667 |
| Retevmo | 15 | $256,994 | $17,133 |
| Mekinist | 14 | $208,343 | $14,882 |
| Tafinlar | 12 | $164,755 | $13,730 |
| Ondansetron | 26 | $553 | $21 |
See all 8 drugs
| Lenvima | 32 | $725,335 | $22,667 |
| Retevmo | 15 | $256,994 | $17,133 |
| Mekinist | 14 | $208,343 | $14,882 |
| Tafinlar | 12 | $164,755 | $13,730 |
| Ondansetron | 26 | $553 | $21 |
| Levothyroxine | 29 | $282 | $10 |
| Oxycodone | 15 | $159 | $11 |
| Gabapentin | 12 | $99 | $8 |
Year by year
| 2024 | 272 | 64 | 7% (19) | None | $1,509,955 |
| 2023 | 261 | 66 | 7% (18) | 19% | $557,153 |
| 2022 | 209 | 47 | 12% (26) | None | $505,016 |
| 2021 | 204 | 44 | 9% (18) | 36% | $572,468 |
| 2020 | 236 | 57 | 9% (20) | 18% | $305,069 |
| 2019 | 622 | 109 | 13% (79) | None | $789,856 |
| 2018 | 552 | 92 | 11% (63) | None | $831,832 |
| 2017 | 357 | 63 | 10% (34) | 25% | $522,313 |
| 2016 | 268 | 58 | 20% (53) | None | $298,163 |
| 2015 | 397 | 84 | 11% (43) | None | $220,720 |
| 2014 | 361 | 60 | 14% (51) | None | $37,456 |
| 2013 | 302 | 63 | 11% (34) | 16% | $24,111 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 4 drugs
| Ondansetron | 26 | $427 | $16 |
| Levothyroxine | 44 | $367 | $8 |
| Prochlorperazine Maleate | 15 | $187 | $12 |
| Oxycodone | 13 | $139 | $11 |
2022: 6 drugs
| Mekinist | 13 | $186,335 | $14,333 |
| Tafinlar | 13 | $145,420 | $11,186 |
| Oxycodone | 20 | $279 | $14 |
| Ondansetron | 17 | $216 | $13 |
| Levothyroxine | 17 | $205 | $12 |
| Prochlorperazine Maleate | 12 | $137 | $11 |
2021: 10 drugs
| Lenvima | 12 | $246,197 | $20,516 |
| Mekinist | 13 | $175,678 | $13,514 |
| Tafinlar | 13 | $132,217 | $10,171 |
| Synthroid | 11 | $443 | $40 |
| Oxycodone | 15 | $355 | $24 |
| Ondansetron | 15 | $352 | $23 |
| Levothyroxine | 20 | $318 | $16 |
| Gabapentin | 11 | $173 | $16 |
| Lorazepam | 12 | $66 | $5 |
| Lisinopril | 12 | $33 | $3 |
2020: 7 drugs
| Hydrocodone-Acetaminophen | 16 | $689 | $43 |
| Ondansetron | 34 | $519 | $15 |
| Prochlorperazine Maleate | 24 | $279 | $12 |
| Levothyroxine | 19 | $221 | $12 |
| Gabapentin | 12 | $102 | $9 |
| Lorazepam | 14 | $36 | $3 |
| Lisinopril | 12 | $24 | $2 |
2019: 11 drugs
| Lenvima | 23 | $384,114 | $16,701 |
| Gilotrif | 12 | $111,616 | $9,301 |
| Xarelto | 12 | $5,361 | $447 |
| Hydrocodone-Acetaminophen | 57 | $2,244 | $39 |
| Gabapentin | 66 | $1,335 | $20 |
| Ondansetron | 57 | $1,117 | $20 |
| Prochlorperazine Maleate | 100 | $966 | $10 |
| Nystatin | 13 | $521 | $40 |
| Dexamethasone | 20 | $369 | $18 |
| Levothyroxine | 46 | $268 | $6 |
| Lorazepam | 25 | $104 | $4 |
2018: 13 drugs
| Lenvima | 32 | $446,553 | $13,955 |
| Alecensa | 11 | $146,540 | $13,322 |
| Xarelto | 21 | $9,693 | $462 |
| Gabapentin | 65 | $1,293 | $20 |
| Hydrocodone-Acetaminophen | 32 | $887 | $28 |
| Ondansetron | 55 | $474 | $9 |
| Nystatin | 15 | $405 | $27 |
| Prochlorperazine Maleate | 50 | $321 | $6 |
| Dexamethasone | 11 | $202 | $18 |
| Oxycodone | 11 | $176 | $16 |
| Levothyroxine | 24 | $123 | $5 |
| Lorazepam | 19 | $99 | $5 |
| Mirtazapine | 12 | $80 | $7 |
2017: 10 drugs
| Imatinib Mesylate | 11 | $109,746 | $9,977 |
| Gabapentin | 30 | $632 | $21 |
| Hydrocodone-Acetaminophen | 21 | $468 | $22 |
| Ondansetron | 31 | $344 | $11 |
| Levothyroxine | 26 | $214 | $8 |
| Prochlorperazine Maleate | 25 | $156 | $6 |
| Dexamethasone | 12 | $122 | $10 |
| Lorazepam | 18 | $104 | $6 |
| Prednisone | 12 | $85 | $7 |
| Sertraline | 12 | $79 | $7 |
2016: 5 drugs
| Hydrocodone-Acetaminophen | 26 | $1,363 | $52 |
| Ondansetron | 40 | $315 | $8 |
| Gabapentin | 20 | $167 | $8 |
| Prochlorperazine Maleate | 20 | $153 | $8 |
| Sertraline | 13 | $70 | $5 |
2015: 11 drugs
| Gleevec | 12 | $120,196 | $10,016 |
| Linzess | 11 | $3,108 | $283 |
| Hydrocodone-Acetaminophen | 15 | $577 | $38 |
| Omeprazole | 28 | $393 | $14 |
| Pantoprazole | 15 | $307 | $20 |
| Gabapentin | 16 | $300 | $19 |
| Dexamethasone | 26 | $298 | $11 |
| Ondansetron | 20 | $268 | $13 |
| Gavilyte-N | 13 | $238 | $18 |
| Levothyroxine | 24 | $228 | $9 |
| Prochlorperazine Maleate | 22 | $123 | $6 |
2014: 9 drugs
| Hydrocodone-Acetaminophen | 17 | $417 | $25 |
| Ondansetron | 33 | $351 | $11 |
| Oxycodone | 12 | $303 | $25 |
| Omeprazole | 28 | $262 | $9 |
| Gavilyte-N | 13 | $245 | $19 |
| Prochlorperazine Maleate | 33 | $165 | $5 |
| Dexamethasone | 13 | $110 | $8 |
| Citalopram Hbr | 22 | $84 | $4 |
| Lorazepam | 14 | $65 | $5 |
2013: 5 drugs
| Omeprazole | 42 | $555 | $13 |
| Hydrocodone-Acetaminophen | 19 | $356 | $19 |
| Ondansetron | 20 | $285 | $14 |
| Gavilyte-N | 12 | $193 | $16 |
| Prochlorperazine Maleate | 22 | $115 | $5 |
Money from drug and device companies
$7,267 in 2024
| 2024 | 8 | 20 | $5,865 | $7,267 |
| 2023 | 8 | 23 | $41,703 | $42,356 |
| 2022 | 6 | 21 | $74,508 | $74,732 |
| 2021 | 3 | 15 | $63,280 | $63,291 |
| 2020 | 11 | 24 | $54,313 | $54,583 |
| 2019 | 12 | 32 | $18,760 | $19,816 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Genmab U.S. | Tivdak | $5,689 | 10 payments
|
| Coherus Biosciences | Loqtorzi | $1,350 | 1 payment
|
| Abbvie | Imbruvica | $63 | 2 payments
|
| Regeneron Healthcare Solutions | Libtayo | $45 | 2 payments
|
| Astellas Pharma US | Padcev | $42 | 2 payments
|
| Daiichi Sankyo | Enhertu | $29 | 1 payment
|
See all 20 published payments
| Janssen Biotech | Meals · 2024-12-05 | Erleada | $26 |
| Abbvie | Meals · 2024-11-26 | Imbruvica | $31 |
| Daiichi Sankyo | Meals · 2024-11-04 | Enhertu | $29 |
| Genmab U.S. | Consulting · 2024-08-30 | Tivdak | $4,515 |
| Genmab U.S. | Meals · 2024-08-17 | Tivdak | $65 |
| Genmab U.S. | Meals · 2024-08-17 | Tivdak | $14 |
| Genmab U.S. | Travel · 2024-08-17 | Tivdak | $76 |
| Genmab U.S. | Meals · 2024-08-17 | Tivdak | $51 |
| Genmab U.S. | Meals · 2024-08-16 | Tivdak | $11 |
| Genmab U.S. | Travel · 2024-08-16 | Tivdak | $194 |
| Genmab U.S. | Travel · 2024-08-16 | Tivdak | $33 |
| Genmab U.S. | Meals · 2024-08-16 | Tivdak | $22 |
| Genmab U.S. | Travel · 2024-08-12 | Tivdak | $709 |
| Regeneron Healthcare Solutions | Meals · 2024-07-17 | Libtayo | $18 |
| Regeneron Healthcare Solutions | Meals · 2024-06-27 | Libtayo | $27 |
| Incyte | Meals · 2024-06-05 | Jakafi | $23 |
| Astellas Pharma US | Meals · 2024-05-14 | Padcev | $25 |
| Coherus Biosciences | Paid to speak or teach · 2024-04-30 | Loqtorzi | $1,350 |
| Abbvie | Meals · 2024-01-17 | Imbruvica | $32 |
| Astellas Pharma US | Meals · 2024-01-09 | None | $16 |
See earlier years (2023, 2022, 2021, 2020, 2019)
2023: $42,356
| Foundation Medicine | Foundationone Cdx | $35,100 | 10 payments
|
| Coherus Biosciences | None | $4,500 | 2 payments
|
| Eisai | Lenvima | $2,573 | 3 payments
|
| Astellas Pharma US | Xtandi | $82 | 4 payments
|
| Amgen | Lumakras | $27 | 1 payment
|
| Genentech USA | Lunsumio | $26 | 1 payment
|
| Abbvie | Venclexta | $25 | 1 payment
|
| Janssen Biotech | Erleada | $23 | 1 payment
|
2022: $74,732
| Foundation Medicine | Foundationone Cdx | $68,983 | 13 payments
|
| Eisai | Lenvima | $3,800 | 1 payment
|
| Merck KGaA | None | $1,725 | 2 payments
|
| E.R. Squibb & Sons L.L.C. | Opdivo | $118 | 1 payment
|
| Incyte | Monjuvi | $63 | 3 payments
|
| Coherus Biosciences | Udenyca | $43 | 1 payment
|
2021: $63,291
| Foundation Medicine | Foundationone Cdx | $59,125 | 12 payments
|
| Eisai | Lenvima | $4,155 | 2 payments
|
| Merck Sharp & Dohme | Keytruda | $11 | 1 payment
|
2020: $54,583
| Foundation Medicine | Foundationone Cdx | $52,750 | 11 payments
|
| Eisai | Lenvima | $1,587 | 2 payments
|
| Eli Lilly and | None | $52 | 1 payment
|
| Biotronik | None | $46 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $27 | 2 payments
|
| Amgen | Nplate | $27 | 1 payment
|
| Lilly USA | Verzenio | $26 | 2 payments
|
| Novartis Pharmaceuticals | Piqray | $22 | 1 payment
|
| Alexion Pharmaceuticals | Ultomiris | $18 | 1 payment
|
| Janssen Biotech | Erleada | $15 | 1 payment
|
| Incyte | Jakafi | $14 | 1 payment
|
2019: $19,816
| Foundation Medicine | Foundationone Liquid | $15,050 | 7 payments
|
| Genentech | Tecentriq | $4,432 | 5 payments
|
| Eisai | Lenvima | $63 | 3 payments
|
| Merck Sharp & Dohme | Lynparza | $57 | 5 payments
|
| Mylan Institutional | Fulphila | $44 | 2 payments
|
| Incyte | Jakafi | $33 | 2 payments
|
| Lilly USA | Verzenio | $31 | 2 payments
|
| AstraZeneca Pharmaceuticals LP | Calquence | $30 | 2 payments
|
| Amgen | Kyprolis | $22 | 1 payment
|
| AbbVie | Venclexta | $21 | 1 payment
|
| Seattle Genetics | Adcetris | $19 | 1 payment
|
| Pharmacyclics LLC An AbbVie | Imbruvica | $15 | 1 payment
|
Research money
Money a company paid to run a study. Where it went to their institution, the clinician is named as an investigator and did not receive it; the amount covers the whole study, often across many sites.
| Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2023 | Their institution | $428,662 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2019 | Their institution | $392,915 |
| PFIZER INC. · A Phase 1b2 Openlabel Study To Evaluate Safety Clinical Activity Pharmacokinetics and Pharmacodynamics of Avelumab Msb0010718c in Combination With Other Cancer Immunotherapies in Patients With Advanced Malignancies · 2019 | Their institution | $261,205 |
| Merck Sharp & Dohme LLC · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2022 | Their institution | $235,296 |
| Merck Sharp & Dohme LLC · Study Name#Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplastic,Undifferentiated Thyroid Cancer · 2024 | Their institution | $157,056 |
| Merck Sharp & Dohme LLC · Study Name#Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplastic,Undifferentiated Thyroid Cancer · 2025 | Their institution | $140,158 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma La Hnscc · 2020 | Their institution | $136,066 |
| Genentech, Inc. · A Phase Ia Ib Open Label Dose Escalation Study of the Safety and Pharmacokinetics of Xmab24306 Alo · 2024 | Their institution | $115,900 |
| Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2021 | Their institution | $111,783 |
| Genentech, Inc. · A Phase Ia Ib Open Label Dose Escalation Study of the Safety and Pharmacokinetics of Xmab24306 Alo · 2025 | Their institution | $108,436 |
| Merck Sharp & Dohme Corporation · Phase II Trial of Pembrolizumab in Metastatic Or Locally Advanced Anaplasti · 2019 | Their institution | $81,985 |
| Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy With Or Without Pembrolizumab Mk-3475 in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer Nsclc Participants Keynote-789 · 2019 | Their institution | $62,482 |
| AbbVie, Inc. · 2019 | Their institution | $61,336 |
| BeOne Medicines USA, Inc. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2025 | Their institution | $58,211 |
| BeiGene, Ltd. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2024 | Their institution | $52,040 |
| Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed Platinum Chemotherapy With Or Without Pembrolizumab Mk-3475 in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer Nsclc Participants Keynote-789 · 2020 | Their institution | $43,920 |
| Merck Sharp & Dohme Corporation · A Phase III, Randomized, Open-Label Study To Evaluate Pembrolizumab As Neoadjuvant Therapy and in Combination With Standard of Care As Adjuvant Therapy for Stage III-Iva Resectable Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (La Hnscc) · 2019 | Their institution | $43,323 |
| BeiGene, Ltd. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2025 | Their institution | $38,248 |
| BeiGene USA, Inc. · A Randomized, Phase 2, Open-Label, Multi-Arm Study of Tislelizumab in Combination With Investigational Agents As First-Line Treatment in Patients With Recurrent Or Metastatic Head and Neck Squamous Cell Carcinoma · 2025 | Their institution | $28,370 |
| Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2020 | Their institution | $26,599 |
| Ascendis Pharma, Inc. · A Study of Transcon Tlr7/8 Agonist With Or Without Pembrolizumab in Patients With Advanced Or Metastatic Solid Tumors · 2022 | Their institution | $25,286 |
| Ascendis Pharma Inc · Phase 1/2, Open-Label, Dose Escalation and Dose Expansion Study of Transcon Tlr7/8 Agonist Alone Or in Combination With Pembrolizumab in Participants With Locally Advanced Or Metastatic Solid Tumor Malignancies · 2023 | Their institution | $24,320 |
| Eli Lilly and Company · A Phase 1 Study of Oral Loxo-292 in Adult Patients With Advanced Solid Tumors Harboring Ret Alterations · 2019 | Their institution | $24,306 |
| AbbVie Inc. · 2020 | Their institution | $21,701 |
| Merck Sharp & Dohme Corporation · A Randomized, Double-Blind, Phase 3 Study of Pemetrexed + Platinum Chemotherapy With Or Without Pembrolizumab (Mk-3475) in Tki-Resistant Egfr-Mutated Tumors in Metastatic Non-Squamous Non-Small Cell Lung Cancer (Nsclc) Participants (Keynote-789) · 2019 | Their institution | $21,662 |
| Merck Sharp & Dohme Corporation · A Phase 3 Clinical Trial of Pembrolizumab Mk-3475 in First Line Treatment of Recurrent,Metastatic Head and Neck Squamous Cell Carcinoma · 2019 | Their institution | $16,851 |
| Bayer HealthCare Pharmaceuticals Inc. · Clinical Trial Pase IV (Post Marketing) (Bayer Product Or Ta) · 2020 | Their institution | $10,894 |
| Bayer HealthCare Pharmaceuticals Inc. · Bay2757556, Open Label Basket Trial · 2022 | Their institution | $6,067 |
| Bayer HealthCare Pharmaceuticals Inc. · Clinical Trial Pase IV (Post Marketing) (Bayer Product Or Ta) · 2019 | Their institution | $4,062 |
| Genentech, Inc. · Ph III Study To Evaluate the Efficacy and Safety of Astegolimab in Copd · 2025 | Their institution | $2,837 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1083767024
- Licence
- CA C164010, TX P3742California C164010: Current · expires 2027-08-31Texas P3742: Active
- Group
- Stanford Health Care
- Video visits
- Lists video visits
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Medical oncology (207RX0202X); Federal specialty code 207RH0000X (207RH0000X); Federal specialty code 207RH0003X (207RH0003X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2007-01-22
- NPI last updated
- 2024-04-25
- NPI record certified
- 2024-04-25
This is when the NPI record was last certified, not a medical board exam.